Breast Cancer Now media statements
We respond to NICE’s approval of trastuzumab deruxtecan (Enhertu) for use on the Cancer Drugs Fund
Chief Executive of Breast Cancer Now, Baroness Delyth Morgan, has commented on NICE'S decision to approve trastuzumab deruxtecan for use on ...
We respond to double SMC drug announcement - adjuvant abemaciclib and alpelisib with fulvestrant
Chief Executive of Breast Cancer Now, Baroness Delyth Morgan, has commented on the double announcement by the Scottish Medicines Consortium.
Pembrolizumab in combination with chemo is approved for use on the NHS in Scotland
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to research about a potential new treatment for advanced breast cancer patients
Dr Kotryna Temcinaite, senior research communications manager at Breast Cancer Now, said:
We welcome approval of palbociclib with fulvestrant for routine use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said the approval of palbociclib with fulvestrant for routine use on the NHS w...
Fantastic outcome for certain patients with incurable secondary triple negative breast cancer as pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) is approved for use on the NHS in Scotland
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said that the approval of pembrolizumab (Keytruda) in combination with chemo f...
Breast Cancer Now responds to latest NHSE Cancer Wait Times data, calling for the FDS to be raised to 95%
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, responded to the latest NHS England cancer waiting times data, calling for the...
We respond to NHS England breast cancer waiting times: January 2022
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said: